Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate
- PMID: 2037383
- PMCID: PMC257992
- DOI: 10.1128/iai.59.6.2215-2218.1991
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate
Abstract
Gestating Holstein cows were vaccinated with Clostridium difficile toxoid prepared from the culture filtrate of a strain that produces high levels of toxins A and B and other antigens. A bovine immunoglobulin G (IgG) concentrate was prepared from colostrum collected at parturition. The results of our studies showed that hamsters treated prophylactically with the hyperimmune bovine IgG concentrate were protected against C. difficile disease. These results suggest that orally administered hyperimmune bovine IgG specific for C. difficile culture filtrate may be useful in prophylaxis against C. difficile disease.
Similar articles
-
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.Infect Immun. 2011 Jun;79(6):2295-302. doi: 10.1128/IAI.00130-11. Epub 2011 Apr 11. Infect Immun. 2011. PMID: 21482682 Free PMC article.
-
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.Infect Immun. 1995 Dec;63(12):4619-27. doi: 10.1128/iai.63.12.4619-4627.1995. Infect Immun. 1995. PMID: 7591115 Free PMC article.
-
Active and passive immunization to protect against antibiotic associated caecitis in hamsters.Dev Biol Stand. 1983;53:325-32. Dev Biol Stand. 1983. PMID: 6873474
-
Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile.Hum Vaccin Immunother. 2013 Jul;9(7):1565-8. doi: 10.4161/hv.24078. Epub 2013 Feb 22. Hum Vaccin Immunother. 2013. PMID: 23435084 Review.
-
Active and passive immunization against Clostridium difficile diarrhea and colitis.Vaccine. 2004 Feb 17;22(7):848-56. doi: 10.1016/j.vaccine.2003.11.030. Vaccine. 2004. PMID: 15040937 Review.
Cited by
-
A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.Clin Vaccine Immunol. 2013 Mar;20(3):377-90. doi: 10.1128/CVI.00625-12. Epub 2013 Jan 16. Clin Vaccine Immunol. 2013. PMID: 23324518 Free PMC article.
-
Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.Microb Cell Fact. 2021 Apr 22;20(1):88. doi: 10.1186/s12934-021-01576-5. Microb Cell Fact. 2021. PMID: 33888152 Free PMC article. Review.
-
Neutralization of Clostridium difficile toxin A using antibody combinations.MAbs. 2010 Mar-Apr;2(2):190-8. doi: 10.4161/mabs.2.2.11220. MAbs. 2010. PMID: 20150758 Free PMC article.
-
Recurrent Clostridium difficile infection: what are the treatment options?Drugs. 2011 May 7;71(7):853-68. doi: 10.2165/11591230-000000000-00000. Drugs. 2011. PMID: 21568363 Review.
-
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.Gut. 1997 Sep;41(3):366-70. doi: 10.1136/gut.41.3.366. Gut. 1997. PMID: 9378393 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases